Cintas Corp (NASDAQ: CTAS) reported upbeat earnings on Wednesday, beating analyst expectations on earnings and sales by 8.4% and 3.9%, respectively. The fiscal Q1 2023 included EPS of $3.39 and revenues of $2.16bn. It also raised full-year guidance.

#What Does Cintas Corp Do?

Cintas Corporation designs, manufactures and implements corporate identity uniform programs. The company also provides entrance mats, mops, restroom supplies, promotional products, document management, fire protection, and first aid and safety services.

Cintas Corporation is an American corporation headquartered in Mason, Ohio. Richard T. Farmer founded the company in 1968.

Farmer grew the company through acquisitions and start-ups, transforming it from a small family business into a billion-dollar public company. Mr. Farmer died in August 2021, aged 86. His son Scott D Farmer is the current Executive Chairman at Cintas.

Cintas is a publicly held Fortune 500 company traded over the Nasdaq Global Select Market under the symbol CTAS. It is a component of the Standard & Poor's 500 Index and Nasdaq-100 Index.

We covered CTAS stock in this week's earnings preview.

#How Does Cintas Corp Make Money?

Cintas Corp makes money from three divisions. Its most significant revenue stream comes from renting uniforms and facility services. It also makes money in first aid and safety services. Its third revenue stream includes fire protection services and uniform direct sales.

Total revenue grew 14.2% in Q1, and each business unit grew revenue at a double-digit rate.

Meanwhile, operating cash flow is up 13.7% Y/Y, and free cash flow is up 7%. 

The company raised its full-year revenue expectations to $8.58bn and $8.67bn. 

Cintas also raised EPS guidance to range between $12.30 and $12.65. And it expects operating income to be between $1.72bn and $1.76bn, compared to $1.55bn in the fiscal year 2022.

Todd M. Schneider, Cintas' President and CEO, stated:

We are pleased with our fiscal 2023 first quarter financial results. These financial results are the product of the continued focus of our employee-partners on providing businesses with the image, safety, cleanliness and compliance needed to help our customers get Ready for the Workday®.

#CTAS Stock Financials

Over the past year, CTAS stock has traded between $343.86 and $461.44. Today it trades at around $390. Year-to-date, the Cintas stock price is down by -7%, while the S&P 500 is down by -22.46% over the same period.

FactSet analysts have a consensus Overweight rating on CTAS stock with a target share price of $444.

CTAS stock has a price-to-earnings ratio (P/E) of 33, and its price-to-book-value (P/BV) is 12.4, indicating that it may be overvalued. CTAS stock comes with a dividend yield of 1.2%.

#Cintas Corp Growth Potential

• Cintas Corporation helps more than one million businesses of all types and sizes get Ready™ to open their doors with confidence every day by providing products and services that help keep their customer's facilities and employees clean, safe and looking their best.

• The company aims to deliver high-quality products and services, which come at a justifiably higher price than its competitors.

• Cintas has taken the initiative to make some bold business decisions that are paying off. For instance, it has brought some recognizable brand names to the uniform rental division, including Carhartt, Chef Works and Landau. This complements its aim to provide quality workwear. 

• The company is optimistic in its outlook for the rest of the year, although it does face tougher comps Y/Y and expects a slight deceleration from its current growth levels.

• Nevertheless, Cintas is enjoying positive momentum, which it hopes will translate into wider margins. It has also raised prices to combat inflation and has not experienced pushback in this regard. 

• The company is immensely proud of its motivated sales force, which is well-trained and positioned to deliver.

#CTAS Stock Risks

• The labor environment continues to pose a challenge. Higher wages and incentives are required to retain staff.

• A broader economic downturn could slow demand for Cintas' products and services.

#Is CTAS Stock a Good Investment?

Cintas is a solid company with a strong track record, impressive growth, and a dividend yield. Its financial metrics are at the high end, as is to be expected for a stock that's outperforming its peers.

For existing CTAS shareholders, it's probably wise to hold, but as there are many headwinds facing the markets today, it may be better to wait for a lower price point to buy shares in CTAS. Nevertheless, for investors with a long time horizon, Cintas seems like a good company that is likely to weather the storm. 

The Cintas AGM is scheduled for Tuesday, October 25, 2022.

#If you enjoyed our Cintas Corp coverage, you may be interested in our recent Daily Stock Watch articles or our IPO coverage.

Provention Bio (NASDAQ: PRVB) is moving on up, rising by more than 20% this morning after it entered into a co-promotion agreement with Sanofi (NASDAQ: SNY).

The agreement, which concerns collaboration for the launch of Provention's lead investigational drug candidate teplizumab, sees Provention receive a $20m non-refundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for type 1 diabetes.

#Provention's Sanofi Agreement

Under the terms of the agreement, Sanofi will commit commercial resources in the United States, including diabetes field specialists, account directors, field-based reimbursement and medical science liaisons to expand the number of key healthcare professionals reached in the United States.

In exchange, Provention will reimburse field force-related expenses that Sanofi will incur in connection with commercializing teplizumab under the agreement.

Provention Bio Chief Commercial Officer, Jason Hoitt, commented:

"This collaboration with Sanofi US allows us to significantly expand our planned commercial footprint during launch to support increased screening and product awareness as we work to launch a new therapy that, if approved, will dramatically impact the lives of the patients and families we serve.

“In particular, Sanofi's long-standing relationships with key U.S. healthcare professionals will complement our focus on pediatric endocrinologists and help us address a larger patient population with greater efficiency.” 

It sounds like an exciting deal, but does it make PRVB stock a good investment?

#What is Provention Bio?

Provention Bio is a clinical stage biopharmaceutical company which is focused on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases.

Its product candidates include PRV-031 teplizumab and monoclonal antibodies (mAb), which is in Phase III clinical trial for the interception of type one diabetes.

Other candidates include PRV-3279, which has completed a Phase Ib clinical trial for the treatment of lupus, as well a coxsackie virus B vaccine PRV-101 and celiac disease treatment PRV-015.

The company has a license and collaboration agreement with Amgen (NASDAQ: AMGN) for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease.

Additionally, it has a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China.

The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Want to find out more about biopharma? CLICK HERE to find out how biopharma stocks could boost your portfolio!

#How Does Provention Bio Make Money?

While the company has yet to commercialize its own products, it has received collaborative revenue from its work with Hangzhou Zhongmei Huadong Pharmaceutical Co, with these amounting to $0.7m in the company’s second quarter, $0.5m in the first quarter and $1.4m in the company’s 2021 financial year.

#PRVB Stock Financials

The company’s most recent earnings release showed it achieved revenue of $746k in its second quarter, compared with nil in the same period one year prior. This didn’t make much of a dent in Provention Bio’s operating expenses, which amounted to $30.6m for the period. This was roughly flat when viewed against expenses of $30.2m from Q2 2021.

This imbalance means the business recorded a net loss of $29.7m for the period.

Provention Bio had cash, cash equivalents and marketable securities of $96.1m as of 30 June 2022. However, the business has since secured a term loan facility of up to $125m with Hercules Capital (NYSE: HTGC), a specialist in customized financing for companies in life sciences.

The company does not distribute a dividend to its shareholders.

#PRVB Growth Potential

In the near term, the company's potential seems to hinge on the success of its teplizumab treatment.

The company is nearest to commercialization with its teplizumab treatment for the purpose of delaying type 1 diabetes in at-risk patients. Some trials of the treatment have suggested that it can delay the onset of type 1 diabetes by as much as three years by altering T Cells and interrupting the condition.

The business has a user fee goal date for this treatment of 17 November 17 2022 from the US Food and Drug Administration (FDA). 

The company has additionally been informed that if no major deficiencies are identified during this ongoing review period, the FDA plans to communicate proposed labeling and, if necessary, any post-marketing requirement or commitment requests by 17 October 2022. 

Estimated US prevalence of at-risk patients amounts to as many as 200,00 people, with Provential Bio intending to initially target the 15% of this group who are relatives of type 1 diabetes patients.

The treatment is also at phase 3 for use among newly diagnosed patients.

Figures from Provential Bio suggest that there are approximately 64,000 new cases of type 1 diabetes in the US each year, with 26% of these being of the 8- to 17-year-old age group that the company is seeking to target with its market launch. In future, the company intends to target other age groups too. 

Additionally, the company believes that teplizumab has potential for broad applicability in T cell-mediated immune diseases, with potential new therapeutic indications including Crohn’s disease, autoimmune hepatitis and early rheumatoid arthritis.

#PRVB Investment Risks

As with any development stage biopharma company there are implicit risks in investing in PRVB stock. Primary among these is the risk that the company may be unsuccessful in every bringing any of its product candidates to commercialization.

This could be because they fail to pass through clinical trials with successful outcomes, because they are not approved by regulators or because the company runs out of money to continue operating.

However, it is worth bearing in mind that the business appears well funded for around 18 months considering its considerable cash reserves and recently secured loan.

Additionally, the new deal with Sanofi has added additional cash to Provention Bio’s coffers and also indicates a significant degree of confidence that its primary treatment candidate will make it to the commercial stage in the near future.

Even so, there are still risks. Primarily, the treatment could not be as successful as previously hoped and could be less widely adopted than hoped. 

#Is PRVB Stock a Good Investment?

Provention Bio looks like a company speeding towards commercialization with some real promise. Though revenues are not currently significant and its product candidates are not yet on the market, the business appears well-funded and has received a significant vote of confidence from both Sanofi and Hercules Capital.

That being said, there are always serious risks involved with investing in pharmaceutical companies at this stage. Backing PRVB stock could lead to attractive returns for investors, but there is no guarantee of success.

Of the eight analysts covering the stock for Wall Street Journal, seven have a Buy rating for PRVB. Additionally, the consensus price target for the stock is $13.63, compared with its current price of $5.95 per share at the time of writing.

#If you enjoyed our Provention Bio coverage, you might be interested in our recent Daily Stock Watch articles or our IPO coverage.

In the first six months of 2022, CVE stock soared. Since then, it has witnessed a volatile trend downwards. Bullish investors in the stock believe the global energy crisis will see this stock come good in the end. But shareholders can expect volatility to continue. 

#What Does Cenovus Energy Do?

Cenovus Energy Ltd (NYSE: CVE) operates as an oil and gas company. The company focuses on the production of integrated oils.

Cenovus began independent operations on December 1, 2009, when Encana Corporation split into two distinct companies: an oil company (Cenovus) and a natural gas company (Encana).

Many of Cenovus' original assets were from the two Canadian oil and natural gas companies that merged to form Encana in 2002 - PanCanadian Energy Corp. and Alberta Energy Company. Through these entities, CVE can trace its roots back to the 1880s when the Government of Canada commissioned Canadian Pacific Railway (CPR) to build a transcontinental railroad.

Today, CVE operates oil sands assets in Northern Alberta, which are the cornerstone of its Upstream production business. The company uses a drilling method called steam-assisted gravity drainage – or SAGD for short. Here its operations include three producing oil sands projects in Alberta: Christina Lake, Foster Creek and Sunrise, as well as thermal and heavy oil operations at Lloydminster in Saskatchewan. 

Cenovus Energy serves clients in Canada. 

Earlier this year, Cenovus bought BP's stake in its Sunrise oil sands project in northern Alberta, followed by BP's 50% stake in the Toledo, Ohio refinery for $300m in cash. Additionally, the parties signed a multi-year product supply agreement at Toledo.

Alex Pourbaix, Cenovus President & CEO, said:

Fully owning the Toledo Refinery provides a unique opportunity to further integrate our heavy oil production and refining capabilities,

Operating the refinery will open up additional synergies and capital efficiency opportunities, including connectivity with our nearby Lima Refinery. This transaction solidifies our refining footprint in the U.S. Midwest and increases our ability to capture margin throughout the value chain.

Unfortunately, the BP Toledo refinery experienced a fire last week. Insurance will likely cover the damage, but it may delay CVE's purchase closing date.

#How Does Cenovus Energy Make Money?

Cenovus Energy makes money selling the oil it produces. CVE produces oil from three sources: Oil Sands, Conventional and Offshore. The oil sands are by far its most significant production source. In Q2 of fiscal 2022, CVE saw a quarterly adjusted funds flow of $3.1bn. 

The company has pledged to return money to shareholders via share buybacks when CVE's net debt is below $9bn. In Q2, CVE returned over $1bn via buybacks and reduced net debt to $7.5bn.

#CVE Stock Financials

CVE's market cap has slipped from $45bn in July to $30bn today. Does that mean it's time to buy the dip?

Over the past year, Cenovus Energy Inc (CVE) has traded between $9.17 and $24.91. Today it trades at around $15.45 (CA$21).

Year-to-date, CVE stock is up by 22.33%, while the S&P 500 is down by -23% over the same period.

FactSet analysts have a consensus Buy rating on CVE stock with a target share price of $24.61 (CA$33.43).

CVE stock has a price-to-earnings ratio (P/E) of 10 and its price-to-book-value (P/BV) is 1.6. CVE stock comes with a dividend yield of 2%. 

A stock with a beta higher than 1.0 is expected to be more volatile than the S&P 500. CVE stock has a beta of 2.3, accurately reflecting its volatile nature.

#RBC Capital Markets Rates CVE Stock a Buy

Earlier this month, RBC Capital Markets maintained an Outperform rating on CVE stock with a $32 share price target. The investment bank believes Cenovus Energy has a capable leadership team, strong balance sheet and capital discipline.

It also deems improved shareholder returns via dividends and buybacks a strong possibility going forward.

#Cenovus Energy Growth Potential

The company hopes to generate free cash flow and continue to reduce debt during the second half of 2022. Cenovus also aims to achieve its $4bn net debt target by the end of this year.

#CVE Stock Risks

• The suppressed oil price will likely weigh on the CVE share price in the short term.

• Inflation impacts the company's input costs, and it expects its capital investment costs next year will be higher than previously thought. 

• CVE has grown through M&A; another acquisition could also delay shareholder returns.

• Competitors are operating in the area, some of which may be ahead of CVE in operational aptitude. 

• The recent BP Toledo refinery fire could result in downtime that impacts future cash flow from the deal for CVE. In turn, this could lead to increased capital expenditure, potentially delaying shareholder returns.

#How Much CVE Stock Does the CEO And Other Management Own?

Not much is the short answer. Insiders own around 0.1% of CVE stock, while institutions own 66%. 

• Alex Pourbaix, President and CEO of Cenovus Energy, owns a 0.06% stake in CVE.

• Keith A. J. MacPhail, Chairman for Cenovus Energy, has a 0.04% stake.

• Jonathan M. McKenzie, COO and Executive VP, has a 0.02% stake.

• Via CK Hutchison Holdings, Hong Kong billionaire business magnate Li Ka-Shing owns a 16.4% stake in Cenovus from his prior ownership of Husky Energy.

• The Li family Trust also owns a 12% stake.

#Is CVE Stock a Good Investment?

The success of the CVE stock price is primarily linked to the WTI oil price and company news flow. When the CVE share price was soaring in the first half of the year, the price of oil was elevated over $100 a barrel and briefly spiked above $120. WTI has now come down to around $77.

There are two schools of thought as to how the oil price will land during the winter. A global slowdown and countries like China tapping their reserves could lessen demand and suppress the price for longer, as could mild weather.

Another factor longer-term is the global food crisis exacerbated by drought, which could suppress oil demand if factories are forced to close.

Others believe it's inevitable that demand will climb as the Russia/Ukraine war rages on and cold winters require more oil and gas.

Furthermore, the US released excess oil from its strategic petroleum reserve (SPR), which may at some point need to be replaced, although this point is also debated.

The oil price is also driven by political decisions and therefore remains largely unpredictable.

#
If you enjoyed our Cenovus Energy coverage, you may be interested in our recent Daily Stock Watch articles.

Atlis Motor Vehicles (NASDAQ: AMV) debuted on the NASDAQ in September, with its share price soaring as much as 500%.

The government's push for electrification is hindered by commercial dependence on fossil fuels. Atlis aims to fix that by producing EV battery technology capable of EV usage comparable to current fossil fuel-based medium and heavy-duty trucks. This is a potential game-changer for EV adoption.

As the year comes to a close, AMV stock is down over -94%.

#What Does Atlis Motor Vehicles Do?

Atlis Motor Vehicles is a mobility technology company that provides electric vehicle battery charging technology for passenger comfort and testing and maintenance services in the United States.

Atlis positions itself as a comprehensive electric vehicle technology ecosystem and battery company that is focused on creating an electric work truck, as well as the batteries needed to power it.

Of all US EV companies, Atlis is the only one to develop its own batteries and offer that technology to other companies. Its primary vehicle model, the XT, is built upon an electric vehicle technology platform, the XP Platform, designed for heavy and light-duty work trucks for use in the agriculture, service, utility, and construction industries. It is designed to meet the towing and payload capabilities of legacy diesel-powered vehicles.

Mark Hanchett, Atlis's CEO, commented on its IPO debut:

We are incredibly gratified to have reached this milestone in partnership with our pre-public investors, many of whom have been invested in the Company since its inception,

We now enter this exciting next phase of development for Atlis, in which we have achieved the milestone of becoming a publicly listed company, and now look forward to executing on an ambitious business plan to achieve revenue and profitability in an exciting and emerging market with significant opportunities to differentiate ourselves and tremendous potential to create, maintain and increase shareholder value.

Atlis Motor Vehicles was founded in 2016 and is based in Mesa, Arizona. 

#How Does Atlis Motor Vehicles Make Money?

Atlis Motor Vehicles is not yet making any money. The company anticipates continuing to incur losses and generate negative cash flow from its operations. However, the company hopes to start generating revenue in 2023.

#AMV Stock Financials

AMV debuted at an offering price of $27.50 per share and opened at $30.11. The company offered 1.85 million shares, and interest surged during the night. The following day Atlis share price saw a high of $243.99. Today its share price sits at $4.39.

The company posted a net loss of -$17.3m in the three months that ended June 30, 2022. Up from a -$6.2m loss Y/Y.

Atlis plans to use the proceeds of its IPO to recruit engineers, purchase additional battery testing equipment, expand its sales programs and finalize the production-level design for its XT pickup and XP platform.

#Atlis Motor Vehicles Growth Potential

Last year, Atlis achieved essential milestones and built the foundation on which it plans to grow. This includes producing the first AMV battery cell, which charges in under ten minutes and successfully launching the ATLIS XT truck prototype.

Atlis is targeting the commercial sector, including construction, agriculture, mining, and fleet services, among others, as a key area for growth, as it believes that this segment is not fully served by current electric vehicle manufacturers.

Indeed, Atlis foresees the battery and medium to heavy-duty truck EV markets will grow to $560bn and $15.6bn, respectively, by the year 2030.

Additionally, recent legislation introduced by the United States Government has focused on moving away from traditional fossil fuel-powered vehicles toward the EV space.

#Onwards and Upwards

Atlis has already designed and built proprietary battery technology to rival fossil fuel efficiency in trucks. This technology will allow for a maximum towing capacity of up to 35,000 pounds, a driving range of 300 – 500 miles, and the ability to charge a vehicle from zero percent to a full 100% in under fifteen minutes.

The company is also developing the XP platform. This skateboard chassis can power various models of work vehicles and streamline the vehicle maintenance process with standardized components that are easy to replace or repair. As part of this platform, the company intends to offer a scalable technology solution with a connected cloud, mobile, service and charging ecosystem that will provide what it believes will be unprecedented workflows and customer experience.

The company is also developing a 100% electric, full-sized work truck. 

Additionally, Atlis plans to provide services for its vehicles and platforms, including 1.5 Megawatt charging stations and a subscription service that covers maintenance, insurance and service costs.

Our plan is to begin to sell our proprietary battery packs beginning in fiscal year 2022, followed by the commercialization of our XP Platform in fiscal years 2022 and 2023 and finally, production and delivery of our XT pickup trucks in fiscal 2024.

#AMV Stock Risks

• The company incurs several expenses related to completing its ongoing R&D activities. And inflationary market conditions could increase these input costs.

• The EV space is highly competitive, and stocks tend to perform with extreme volatility.

• In early 2022, the company saw a significant increase in its costs year over year. And with the high expenses associated with going public, it is expected that this trend will continue.

#Is AMV Stock a Good Investment?

As AMV has only recently gone public, it isn't easy to forecast future performance. If it can meet its projected milestones and begin generating revenue next year, that's sure to buoy investor interest. 

In the meantime, investors can expect share price volatility to continue.

#Atlis Motor Vehicles Becomes NXU Inc. (NASDAQ: NXU)

In May 2023, NXU Inc. (NASDAQ: NXU), formerly Atlis Motor Vehicles, Inc., secured overwhelming shareholder approval to transform into a holding company. This change makes Atlis Motor Vehicles a subsidiary of Nxu, Inc. The reorganization aims to amplify value for both customers and shareholders. During a special meeting, almost 100% of the voting shares backed this structural shift and also greenlit an Omnibus Incentive Plan. This plan motivates Nxu's employees, directors, and consultants to invest in the company through stock-based rewards.

This structural change comes on the heels of Nxu's recent rebranding, which aligns the company more closely with its mission to advance electrification in mobility and infrastructure. Nxu will introduce its new ticker symbol, "NXU," on the Nasdaq market on May 15, 2023. This alteration leaves existing stock certificates untouched, and Nxu will conduct all future market activities under its new name and ticker symbol.

Specializing in battery technology, Nxu aims to bolster e-Mobility and energy storage solutions with its innovative technologies and subscription-based models.

#If you enjoyed our Atlis Motor Vehicles coverage, you may be interested in our recent IPO coverage. Some articles you may find useful include:

• What is an IPO?

• The IPO Boom of 2021

• IPO Outlook

The US Food and Drug Administration (FDA) approved Amylyx Pharmaceuticals (NASDAQ: AMLX) drug RELYVRIO (previously known as AMX0035 in the US) for slowing the progression of amyotrophic lateral sclerosis (ALS) and potentially delaying death.

#What Does Amylyx Pharmaceuticals Do?

Amylyx Pharmaceuticals, Inc. operates as a pharmaceutical company. The company develops a proprietary therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Amylyx Pharmaceuticals serves customers worldwide.

AMLX is focused on the development and potential global commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol), for the treatment of ALS.

AMX0035 is commercially named ALBRIOZA in Canada and RELYVRIO in the US.

In June 2022, the drug received marketing authorization from Health Canada, and commercial sales of ALBRIOZA began in the region in Q3. 

ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis and eventually, death. The disorder is sometimes called Lou Gehrig's disease after the baseball player diagnosed with it.

More than 90% of people with ALS have sporadic disease, showing no apparent family history. ALS affects approximately 29,000 people in the United States.

Amylyx Pharmaceuticals' principal drug RELYVRIO is an oral, fixed-dose combination therapy for treating adults with ALS. In the Phase 2 trial involving 137 patients, the outcome showed those taking RELYVRIO lived about ten months longer than those who didn't. The drug also appeared to delay hospitalizations and slow the loss of physical function.

Detailed data from the CENTAUR clinical trial were published in the New England Journal of Medicine, Muscle & Nerve, and the Journal of Neurology, Neurosurgery and Psychiatry.

The FDA approval came with seven positive votes to two. The two negative votes would have liked to wait for Phase 3 results. But the company doesn't expect top-line results from its Phase 3 Phoenix trial until 2024.

#A Controversial Decision

The news is widely welcomed as federal health advisors previously ruled against drug approval in March with six negative votes to four.

The ALS Association, which helped fund Amylyx's research, said the FDA's March review did not consider "the speed and severity of ALS and the few treatment options available."

It's a controversial subject because approving a drug despite uncertainty about its effectiveness could lead to untold problems. This type of approval doesn't usually come before a Phase 3 trial.

Nevertheless, with few treatment options available, patients and their families are desperate for a glimmer of hope.

Indeed, ALS patients and their families have rallied behind Amylyx's drug since its data was first published in 2020. Thus, launching an aggressive lobbying campaign and enlisting members of Congress to push the FDA to grant approval.

Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, said:

Today’s FDA approval of RELYVRIO is an exciting milestone for the ALS community and is a major step toward achieving our mission to one day end the suffering caused by neurodegenerative diseases,

We want to give a heartfelt thank you to the broader ALS community, including healthcare professionals and those living with ALS, for their guidance, support of our clinical programs, and for sharing their experiences with us. Their stories inspired us and helped our team to better understand the ALS clock, instilling in us a deep sense of urgency that will continue to drive us forward. This is just the beginning and there is much more to be done.

However, the FDA approval is based on a small Phase 2 trial, which is not as extensive as would usually be expected in an approval process. But no two diseases are the same, and in the case of ALS, advocates for the drug believe something is better than nothing. 

Leading ALS advocacy organizations remarked in a statement:

Our organizations have been on a mission to create a world free of ALS. With today’s approval, we are encouraged that RELYVRIO can offer people living with ALS and their families the potential of more time with functional independence.

This is especially important for a rapidly progressive disease with a median survival time from diagnosis of just two to three years.

#Adverse Effects

Data from the CENTAUR trial showed the most common adverse events occurring with RELYVRIO (at least 15% and at least 5% greater than placebo) were diarrhea, abdominal pain, nausea, and upper respiratory tract infection. Gastrointestinal-related adverse reactions occurred throughout the study but were more frequent during the first three weeks of treatment.

#How Does Amylyx Pharmaceuticals Make Money?

Amylyx Pharmaceuticals is not yet making money, but with sales of ALBRIOZA in Canada underway, the company has begun generating cash flow in Q3. Now, with the FDA approval of RELYVRIO, this should tick up in the coming year.

After considering the input of many stakeholders throughout the ALS community in the United States, Amylyx decided to price RELYVRIO below the latest FDA-approved product available to people with ALS.

#AMLX Stock Financials

During the first half of 2022, Amylyx made a net loss of -$101.9m compared with a net loss of -$36.4m Y/Y. 

For Q2, Amylyx reported earnings per share (EPS) of -$0.93, missing the FactSet consensus of -$0.87. 

AMLX is expected to report its next earnings update, for Q3, on November 30. FactSet analyst consensus estimates have projected EPS at -$0.97 and sales at $0.13m.

Over the past year, AMLX stock has traded between $6.51 and $33.41. Today it trades at around $33. Year-to-date, the Amylyx Pharmaceuticals stock price is up by 67%, while the S&P 500 is down -24.1% over the same period.

FactSet analysts have an Overweight rating on AMLX stock with a target share price of $44.25.

AMLX stock has a price-to-book-value (P/BV) of 8.9, which is above the industry benchmark of 5.6. AMLX stock does not provide a shareholder dividend.

#Amylyx Pharmaceuticals Growth Potential

As part of its longer-term growth strategy, Amylyx plan to evaluate AMX0035 in other indications and develop additional product candidates.

It may choose to in-license or acquire other product candidates and commercial products to treat patients suffering from neurodegenerative diseases and CNS or other disorders with significant unmet medical needs and limited treatment options.

#AMLX Stock Risks

• AMLX stock went public in January 2022. This comes with larger operating costs, such as legal, accounting, and investor relations. Therefore, the company will likely need additional funding to support its continuing operations and growth strategy. This could potentially lead to stock price dilution.

• Developing additional product candidates will require time-consuming development efforts, including preclinical studies, clinical trials and approval processes.

• All product candidates are prone to the inherent risks of failure in pharmaceutical product development. There are no guarantees of efficacy or safety.

• Economic strains are weighing on stocks, with riskier investments prone to share price destruction.

#Is AMLX Stock a Good Investment?

The FDA approval of RELYVRIO is a pivotal moment for the company and exciting for shareholders. However, the company has not yet disclosed how much it charges for the drug, so it's unclear how much revenue potential it has in the near term.

Pharmaceutical R&D is a risky sector to invest in, and the company will need to raise funds to continue. For several reasons, the AMLX share price will likely remain volatile.

#If you enjoyed our Amylyx Pharmaceuticals coverage, you may be interested in our recent Daily Stock Watch articles or our IPO coverage.

Blue Apron Holdings (NYSE: APRN) stock has started the week with a dive after arriving at a deal to sell around $15m worth of its common stock. The company has reached a deal with Canaccord Genuity for it to act as sales agent, with the deal allowing the business to sell the shares gradually over time.

Blue Apron says net proceeds from this offering for general corporate purposes, including working capital, operating expenses, and capital expenditures.

Additionally, the company has announced that Chief Financial Officer Randy Greben will be leaving his role in mid-October.

In response to these pieces of news, APRN stock has dived by more than 45%.

#What is Blue Apron?

This business operates a direct-to-consumer platform that delivers original recipes with fresh and seasonal ingredients.

It also operates Blue Apron Market, an e-commerce market that provides cooking tools, utensils, pantry items, and other products.

In addition, the company offers Blue Apron Wine, a direct-to-consumer wine delivery service that sells wines, which can be paired with its meals. 

It serves young couples, families, singles, and empty nesters.

The company offers its services through order selections on Website or mobile application primarily in the United States. Blue Apron Holdings, Inc. was founded in 2012 and is headquartered in New York, New York.

#How Does Blue Apron Make Money?

Blue Apron makes money by attracting customers to make purchases through its online storefront or sign up to its various subscription services.

#APRN Stock Financials

APRN stock has a price to sales ratio of 0.36 and a price to book value of 3.69. These compare with respective averages of 0.22 and 3.33 for grocers, according to CSIMarket, potentially indicating that the stock is marginally overvalued. 

Blue Apron’s most recent earnings showed flat revenue of $124.2m in the three months ended 30 June, though net loss deepened from $18.6m to $23.1m as the company faced steeper operating expenses. 

Marketing and costs of goods sold were the biggest drivers behind this, increasing by 33.4% and 4.6% respectively.

Including today’s drop, APRN stock has fallen by more than 49% across the year to date and by more than 55% across the last 12 months. Considering the company’s IPO in June 2017 saw it being priced at north of $11, the share price at the time of writing of $3.27 represents a significant loss to initial investors.

As of September 29, 2022, the company said it had approximately $32.1m in cash and cash equivalents. The company has stated that it is owed $69.4m under two separate agreements but estimates that its cash and cash equivalents, along with the net proceeds from its newly announced offering, will be sufficient to meet anticipated cash needs until sometime in the first quarter of 2023.

The company does not distribute a dividend to its shareholders.

#APRN Investment Risks

The primary risk that the business faces is that it is currently losing customers. The business's most recent earnings update showed that its customer base had declined by 18,000 people to 349,000 customers in the second quarter. This also leaves the business significantly behind where it stood at the same point 12 months prior, when it had 375,000 customers.

Orders per customer were also slightly down at 4.9, compared with 5.3 in Q2 2021, though average order value has climbed from $62.72 to $67.14 across the same time frame.

This comes as the business’ cost of sales is increasing due to inflationary pressure, as well as an increase in shipping and fulfillment packaging costs driven by carrier rate increases and fuel surcharges.

As such, there appears to be a significant danger that the business will continue to see falling customer numbers, while also being unable to significantly lower prices as an incentive for new customers to join.

The business claims that a new brand campaign launched in April 2022 has led to significant success, with higher traffic passing through its website, so perhaps the business’ higher marketing spend will lead to the resurgence in paying customers that Blue Apron needs.  

However, the business faces significant competition from the likes of Gousto and HelloFresh, with a number of other meal kit businesses having emerged since Blue Apron’s dominance of the space back in 2015 and 2016. 

#Is APRN Stock a Good Investment?

Though it achieved enormous growth in the mid-2010s, Blue Apron now looks like a shadow of its former self. The business is struggling to attract new customers while battling higher expenses as the cost-of-living crunch turns consumers on to cheaper options. 

Even worse, the consumers who are willing to fork out for meal kits could well be attracted to Blue Apron’s growing number of competitors. What's more, the efforts to raise money with the recent share sale have understandably made investors jittery.

On the positive side, the business claims a recent marketing push has been encouraging and its partnership with Walmart (NYSE: WMT) could introduce its product to an enormous new audience.

However, it’s difficult to see the stock having much short- or medium-term success in such a challenging environment and competitive sector.

Even so, the three analysts listed by the Wall Street Journal who cover the stock offered a consensus rating of Buy and an average target price of $9.25.

FREYR Battery SA (NYSE: FREY) has seen its share price climb this week after Morgan Stanley analyst Adam Jonas highlighted the stock as one of his top US automotive picks.

Jonas’s research note offered a high-end potential valuation of $60 per share for FREY stock, though his worst-case scenario saw the company’s stock dropping to $4 per share. The report galvanized investors, sending the company’s share price sharply higher on Wednesday.

But what are the ins and outs of FREYR and is FREY stock a good investment?

#What Does FREYR Battery Do?

FREYR Battery is a Norwegian business which is targeting the production of environmentally friendly battery cells.

The company says it is aiming to achieve this through a business model intended to maximize long-term value creation and unlock sustainable, superior returns to its stakeholders.

FREYR plans to develop up to 43 GWh of battery cell production capacity by 2025, which it says will position it as one of Europe’s largest battery cell suppliers.

Its batteries are produced with a reduced carbon footprint thanks to low-cost hydro and wind energy, and are targeted to serve rapidly growing global markets for electric mobility, stationary energy storage, marine and aviation applications.

FREYR has commenced building the first of its planned factories in Mo i Rana, Norway and announced the potential development of industrial-scale battery cell production in Vaasa, Finland and the United States.

#How Does FREYR Battery Make Money?

As of 30 June 2022, the company had not yet initiated manufacturing or derived revenue from its principal business activities. 

However, the company reported in late August that a new partnership with Nidec included a firm sales contract to supply 38 GWh of next-generation clean LFP Lithium-Ion battery cells from 2025 - 2030 combined with a Joint Venture Agreement to develop, manufacture, and sell integrated, low carbon energy storage system (ESS) solutions.

Based on projected raw materials prices, FREYR estimated that the gross value of this contract to the company was in excess of $3bn from 2025 to 2030, which it said represents one of the largest ESS battery cell contracts globally to date.

#FREY Stock Financials

FREY stock currently sits at $15.82, with the share price having climbed by more than 33% across the year to date. The last 12 months have seen the share price hit a high of $15.95 and a low of $6.42.

As of 30 June 2022, the company had cash and cash equivalents of $484.2m and total current liabilities of $43.7m. Additionally, its most recent quarterly earnings saw the business achieve a net income of $4.7m despite operating expenses tripling following a change in fair value of warrant liabilities.

FREYR does not provide its shareholders with a dividend.

#FREY Growth Potential

The company has a strategic plan that it says leaves it well-positioned to become a market leader.

FREYR is using 24M lithium-ion battery production technology for its gigafactory projects in Europe and the US. The business states that this requires less materials than traditional manufacturing, as well as being less energy and labor-intensive. This is expected to help the business gain a competitive advantage when it comes to costs.

Additionally, the business believes its emphasis on decarbonization will yield meaningful cost savings that competitors might not enjoy. 

In short, FREYR anticipates that its lower CO2 footprint relative to conventional producers, as well as a commitment to further decarbonize, should generate a substantial carbon advantage per KWh.

The company believes these factors and more leave it well placed to take advantage of rapidly increasing demand for battery technology. This demand can be seen across multiple industries, with electric vehicle sales more than doubling in 2021 even as the industry faced supply chain and COVID-19 related challenges.

#FREY Investment Risks

The primary risk of investing in the business is that it is not yet at the commercial stage. While FREYR’s strategy and preparations might sound exciting, the company could encounter unexpected difficulties when it actually comes to bring its products to market.

On a similar note, projects like the currently ongoing construction of its new Giga Arctic battery production facility in Norway could encounter difficulties, potentially delaying ramp ups in production which are currently slated for Q1 2023.

Furthermore, excitement surrounding the stock and other EV manufacturers or battery technology developers could lead to the stocks becoming fundamentally overvalued.

Additionally, the company could face fierce competition from other battery manufacturers, particularly other manufacturers who license the 24M process technology that the company will utilize.

#Is FREY Stock a Good Investment?

When you add up everything FREYR has to offer, the company looks like an exciting opportunity. The business appears exceptionally well prepared to take advantage of increasing intensity of demand for battery technology and its emphasis on decarbonization could give it a cutting edge.

Of course, there are risks to investing in FREY stock. Primary among these is that the company has not yet returned significant revenues or brought its battery technology to market.

Analysts covered by the Wall Street Journal gave FREY stock a consensus Buy rating.

Snow Lake Resources (NASDAQ: LITM) is rising on Friday after taking an important step towards building a domestic supply chain for the North American electric vehicle market.

The company has signed a non-binding Memorandum of Understanding with LG Energy Solution to pursue the creation of this supply chain, with the two parties set to collaborate on investigating the possible construction of Canada's first lithium hydroxide processing plants in CentrePort, Winnipeg, Manitoba.

Under the terms of the MOU, Snow Lake Lithium will supply LGES with lithium over a 10-year period once production starts in 2025.

#What Does Snow Lake Resources Do?

Snow Lake Resources is a natural resource exploration company which engages in the exploration and development of mineral resources in Canada, primarily for lithium mineral resources.

It holds interest in the Thompson Brothers Lithium property covering an area of 55,318 acres located in Manitoba.

Snow Lake says its goal is to operate a fully renewable and sustainable lithium mine that can deliver a completely traceable, carbon neutral and zero harm product to the electric vehicle and battery market in North America.

The company was incorporated in 2018 and is based in Winnipeg, Canada.

#The Thompson Brothers Lithium Property

This is the site that Snow Lake Resources is hoping will one day host the world's first all-electric lithium mine. That’s because its operations are set to be powered by renewable hydroelectric power.

According to Snow Lake, the mine is expected to produce 160,000 tonnes of 6% lithium spodumene a year over a 10-year period, which is enough to power 5 million electric vehicles.

Additionally, the project has nearby access to the US rail network via the Arctic Gateway railway, which Snow Lake says reduces transportation to the North American automotive industry from thousands of miles to just several hundred by train.

However, the mine is not expected to commence production until 2025, with engineering evaluation and a drilling program taking place on the site over the coming months as Snow Lake continues to study a 55,000-acre site which it has explored just 1% of at present.

#How Does Snow Lake Resources Make Money?

The company has not yet generated any revenues as its sole asset, the Thompson Brothers property, is still being explored and developed. However, once the project is up and running, which is currently slated to happen in 2025, Snow Lake aims to derive substantial revenues from the sale of lithium hydroxide to the growing EV and battery storage markets in the US and abroad.

#LITM Stock Financials

The company reported it had more than $24.1m in cash remaining at the start of 2022 and had registered a net loss of $1.9m in the prior six-month period. The business has acknowledged that further funding will be required before it begins producing significant revenues.

The company’s IPO was in November 2021, with the business listing 3.2 million shares at a price of $7.50. The company’s share price soared by nearly 150% on its first day of trading as the company’s business plan excited investors.

Things have tailed off a little since then, though, with LITM stock’s price sitting at $2.30 at the time of writing, having fallen by more than 60% across the year to date.

#Shareholder Unrest

It is perhaps worth noting that the company’s leadership has been battling a group of ‘concerned shareholders’ who sought to oust Snow Lake’s board. The group said in a press release from July that it was seeking to combat the “dramatic decline and staggering loss of shareholder value under the current board”.

The group particularly sought increased independence for the company’s board, raising concerns that it did not have enough autonomy from CEO Philip Gross.

The release continued:

“In light of the company's dire circumstances and continued deterioration, ineffective management and recent actions by the board, urgent action is not only justified, but necessary.

“The concerned shareholders have taken action to prevent the further destruction of shareholder value and enable the company's shareholders to determine its future direction by calling the special meeting to be held on August 10, 2022.”

However, Snow Lake succeeded in having the shareholder meeting declared null and void in court in late July, with a shareholder meeting called by the board for 15 December instead being the valid event.

#LITM Stock Growth Potential

The company’s unique selling point to investors and customers alike is that it is seeking to become an environmentally friendly lithium miner.

The business aims to be fully powered by renewable energy and says its hard-rock lithium is a less environmentally impactful method of obtaining the resource than the brine production method used by many competitors.

The company clearly believes this will strongly appeal to potential customers, noting that EV manufacturers like Volvo, Honda (NYSE: HMC), Toyota (NYSE: TM), General Motors (NYSE: GM) and Ford (NYSE: F) are shifting focus towards sustainably source materials. 

While this sustainability angle is the company’s USP, the underlying trend it is hoping to exploit is clearly the accelerating demand for lithium. Lithium carbonate prices have roughly tripled across the past 12 months as the popularity of electric vehicles continues to grow.

While 2.5 million EVs were sold worldwide in 2020, analysis from Deloitte indicates that sales could top 30 million per year by 2030.

#LITM Investment Risks

There are a number of important risks to consider before throwing your weight behind Snow Lake Resources:

• Snow Lake does not expect to start generating revenues until the fourth quarter of 2024, at the earliest. The business could run out of money before this.

• The company’s project is still quite some distance from being a producing lithium mine. Its progress could be delayed by unexpected obstacles and its operations may not be as successful as anticipated due to factors such as lower than expected mineral resources.

• Snow Lake will likely require additional funding to implement its business plan. The business may fail to raise the required funds or shareholders may see their holdings diluted.

• There is a high degree of inherent risk in the mining sector. These include, but are not limited to, environmental hazards, industrial accidents, equipment failure, import/customs delays, metallurgical and other processing problems, and regulatory changes.

#Is LITM Stock a Good Investment?

Snow Lake Resources looks like an example of a business perfectly suited to the green transition, with its renewable energy credentials adding to its efforts to produce a resource that is so key to the green transition.

However, the company’s trouble with shareholders is concerning and could end up posing a significant risk to the business’ ability to continue operating if it snowballs out of control. Another concern is that the business remains at least two years from commercial production and costs are likely to ramp up in the meantime.

From this distance, the business’ plans look sound and exciting, but its internal difficulties and rising costs could see the plan derailed. Mining is an intrinsically risky sector, especially miners who are not yet at the production stage.

As such, investors should carefully consider their attitude to risk before backing LITM stock.

FFIE stock is down 84.6% YTD but up 13% today. Does this mean Faraday Future has turned a corner?

#What Does Faraday Future Do?

Faraday Future Intelligent Electric Inc (NASDAQ: FFIE) operates as a luxury mobility ecosystem company. The company develops a mobility ecosystem that integrates clean energy, AI, the internet, and usership models. Faraday Future Intelligent Electric serves customers worldwide. 

The company is a class-defining luxury EV company. The company has pioneered numerous innovations relating to its products, technology, business model, and user ecosystem since its inception in 2014.

FFIE aims to perpetually improve how people move by creating a forward-thinking mobility ecosystem that integrates clean energy, AI, the Internet and new usership models. Faraday Future's first flagship product is the FF 91 Futurist.

Faraday Future intends to build its Ultimate Intelligent Tech Luxury FF 91 Series out of its Californian production plant in Hanford. This facility is currently being built and marks the beginning of Faraday Future's global production platform.

The company addresses its additional future production capacity needs through a contract manufacturing partner in South Korea. It also works with engineering, sales, and operational teams in China and plans to develop a manufacturing setup in China through a joint venture.

Since its founding in 2014, Faraday Future has created significant innovations in technology and products. It aims to redefine the future of intelligent mobility.

#How Does Faraday Future Make Money?

Faraday Future is a development-stage company and has not yet generated any revenue.

The company's anticipated introduction of the FF 91, its first vehicle launch, is expected to generate most of its future income while other vehicles are in development.

The FF 91 was expected to come to market in July 2022, but this has been pushed back, and there is no firm date yet set. 

This luxury model is expected to have a starting price of $180k, with customized models rivalling the Bentley price point of around $300k.

#Is Faraday Future Running Out of Money?

Faraday must raise more funds to bring its FF 91 to market. It continues to pursue financing alternatives with multiple parties, but a misinformation campaign hindered this process.

The company hired an independent law firm to conduct a thorough independent external investigation which found the allegations to be without merit.

Some of Faraday's directors have faced the threat of lawsuits, physical violence and even death.

Now the company has reached a governance resolution with its major shareholders and brought new financing to the table.

• Faraday Future will receive up to $40m in near-term funding through convertible secured notes and warrant exercise payments, subject to certain conditions.

• Under a second financing agreement, it will receive up to $60m in near-term funding from Senyun International Ltd., a Daguan International Ltd. wholly-owned investment entity, in the form of convertible secured notes, also subject to certain conditions.

This $100m will not be enough to get the FF 91 out the door. Faraday is in ongoing discussions with potential financing sources for additional capital required to fund operations through the end of 2022 and beyond. 

In an attempt to conserve cash and reduce expenses, Faraday is cutting its workforce, reducing expenses and implementing payment delay measures. The company's financial condition is undoubtedly worrying, notably coinciding with current economic conditions and rising competition in the luxury EV space.

#FFIE Stock Financials

Over the past year, Faraday Future Intelligent Electric Inc (FFIE) has traded between $0.71 and $11.20. Today it trades at around $0.92.

FFIE stock's market cap has plunged from $897.4m at the end of December to $786.6m at the end of June to $274m today.

During the first half of 2022, Faraday Future's shares outstanding increased from 168.7 million to 302.5 million.

Year-to-date, the Faraday Future Intelligent Electric Inc (FFIE) stock is down by -86.14%, while the S&P 500 is down by -23.8% over the same period.

FactSet analysts have a Hold rating on FFIE stock.

FFIE stock does not come with a dividend.

#Faraday Future Governance Resolution

Faraday Future and its largest shareholder have reached an agreement regarding their governance dispute.

• Its key shareholder FF Top will dismiss its lawsuit against the company and Faraday's Board of directors.

• Meanwhile, Sue Swenson will step down from her role as Executive Chairperson of the company and Chairperson of the Board upon the company receiving $13.5m in net financing proceeds.

• Sue Swenson and Brian Krolicki will step down from the Board upon the company obtaining $85m in incremental financing commitments and $35m in net proceeds.

• Finally, Adam He, a senior executive with extensive public company experience, has been appointed as a new independent board member to Faraday.

• The company has secured a new $100m financing commitment.

#Faraday Future Growth Potential

• Once it brings the FF 91 to market, the company has plans to develop additional luxury EVs. 

• A crucial part of Faraday Future's growth strategy includes developing its business in China.

#FFIE Stock Risks

In the short term, there are many risks associated with FFIE stock. These include running out of cash, rising inflation, an economic slowdown and increased competition.

• Faraday Future has incurred losses in the operation of its business and anticipates that it will continue to incur losses in the future. It may never achieve or sustain profitability.

• Even if the company brings its FF 91 series to market, it may continue to incur substantial losses as it attempts to develop newer products. 

• There may be a lack of demand for the FF 91 series and its relevant services due to increasing competition, challenging macroeconomic conditions, or regulatory changes.

• Growing in China is in jeopardy as the former CEO of Faraday Future, Jia Yueting is restricted from working for Faraday in China, and the company relies on him to develop its business there.

#How Much FFIE Stock Does the CEO And Other Management Own?

Jordan Vogel, Lead Independent Director of Faraday Future's Board, owns 1.4% of Faraday Future Intelligent Electric. Faraday Future went public via Vogel's SPAC Property Solutions Acquisition Corp. in 2020.

Interestingly, Palantir Technologies (NYSE: PLTR) owns 0.76%, as it was an early investor in the firm. And Faraday also uses Palantir's software under a four-to-six-year commercial contract.

Meanwhile, China's Evergrande Group has a 20% stake in FFIE stock, and FF Top Holding owns 16.4%.

#Is FFIE Stock a Good Investment?

With share price dilution the norm, a real risk of running out of cash, the threat of litigation and a product that's inferior to the competitors in its class, FFIE stock doesn't offer many reasons to invest. 

Broader market conditions are bearish, and a global slowdown in spending is likely. Meanwhile, inflation affects company input costs and encourages consumers to tighten their belts. For now, FFIE stock looks like one to avoid.

#If you enjoyed our Faraday Future coverage, you may be interested in our recent Daily Stock Watch articles.

Nio Inc (NYSE: NIO) stock has fallen alongside other Chinese EV makers this week as investors appear to have lost confidence in the sector. While NIO stock has declined by more than 10% since Monday morning, fellow manufacturers like Li Auto (NASDAQ: LI) and Xpeng Inc (NYSE: XPEV) have also dropped by more than 10%. 

Despite this fear, is NIO stock a good investment?

#What is Nio Inc?

NIO Inc designs develops, manufactures and sells smart electric vehicles in China. It offers five, six and seven-seater electric SUVs, as well as smart electric sedans.

The company is also involved in the provision of energy and service packages to its users, as well as design and technology development activities. These include the manufacturing of e-powertrains, battery packs and components.

In addition, it offers power solutions, a battery swapping service, a fast-charging solution, a mobile charging service through charging vans, an application that provides access to a network of public chargers and their real-time information and a valet service.

Further, the company provides repair, maintenance, and bodywork services through its NIO service centers and authorized third-party service centers; statutory and third-party liability insurance, and vehicle damage insurance through third-party insurers; courtesy vehicle services; roadside assistance; data packages; and auto financing and financial leasing services.

Additionally, it offers NIO Certified, a used vehicle inspection, evaluation, acquisition, and sales service.

The company was formerly known as NextEV and changed its name to Nio in July 2017. The business was incorporated in 2014 and is headquartered in Shanghai, China.

#How Does Nio Inc Make Money?

The vast majority of the company's revenue is derived from vehicle sales. For example, its most recent earnings update showed that 93% of total revenues from the three months ended 30 June came from vehicle sales.

However, other revenues, derived from auto financing services, sales of service, energy packages and sales of used cars, increased the size of their small contribution by 35% during the period.

#NIO Stock Financials

The company's most recent quarter saw it rack up total revenues of $1.5bn, representing an increase of 21.8% from the second quarter of 2021. Vehicle sales climbed by 21% to $1.4bn and other sales climbed by 35%. 

The period also saw cost of sales increase by 30% to $1.3bn due to higher delivery volumes and higher material costs. As such, gross profits declined by 15% to $200.1m. Similar hikes to R&D spending, as well as selling, general and administrative expenses, resulted in Nio's net loss deepening by 370% to $411.7m.

At the end of the period, the company had cash and cash equivalents of $3.7bn. 

NIO stock has a price-to-sales ratio of 4.80 and a price-to-book value of 6.18. These compare with respective averages of 14.82 and 32.69 among auto and truck manufacturers, according to CSIMarket. This could indicate that NIO stock is undervalued. 

Currently, NIO stock sits at a price of $14.77. This represents a decline of more than 55% across the year to date and a drop of around 59% across the last 12 months. The stock has a 12-month high of $44.27 and a low of $11.67.

The company does not distribute a dividend to its shareholders. 

#NIO Growth Potential

Nio delivered 25,059 vehicles in the second quarter of 2022, which is more than 14% growth from the same period a year prior. This growth is expected to accelerate, with the company's operations in the period having been seriously hampered by COVID-19 outbreaks. 

The business' most recent financial results saw Steven Wei Feng, CFO of Nio, comment:

"With the ET7 setting sail to Europe in August, users in more countries will experience our new products and services later this year.

"To meet the growing EV demand of the global market, we have been working closely with our partners to ramp up the production and deliveries of our new products. We also expect to further expand our market share in the global premium smart electric vehicle market with high operating efficiency."

The company aims to sell its EVs in 25 countries by 2025, and its expansion beyond Chinese borders could deliver serious growth as the business has already established itself as a competent manufacturer of reliable vehicles.

#NIO Investment Risks

The company has already faced severe disruption to its operations due to COVID-19 outbreaks in China. Given the country's continued aggressive 'no COVID' policy, it's worth bearing in mind that the business could face further disruption from future outbreaks and surges.

Additionally, it is worth noting that there is fierce competition in the EV space. As well as international businesses like Tesla (NASDAQ: TSLA), General Motors (NYSE: GM) and Ford (NYSE: F) pushing into the Chinese EV space, homegrown businesses like BYD, SGMW and Chery each have significant shares of the domestic market.

Additionally, risk surrounds Chinese stocks on US indexes due to the threat of delisting. In a row over the auditing of Chinese companies listed in the US, The China Securities Regulatory Commission and US Public Company Accounting Oversight Board did manage to sign an agreement in late August.

The two parties agreed on the process for inspecting companies' audit papers after months of concern was kicked off by US regulators accusing Chinese companies failing to adhere with American rules.

Goldman Sachs analysts commented in late August that the market appeared to be "pricing in around 50% probability" that Chinese companies could be delisted from the US.

#Is NIO Stock a Good Investment?

While Nio Inc seems like an exciting investment prospect on the basis of its rapidly growing car sales, there are factors that complicate the picture.

Primary among these is the impact that continued inflation will have on costs for the business, which are already rising faster than revenues. Additionally, the high level of inflation and increasing interest rates make NIO stock unattractive for investors at present, meaning any significant increase in share price is unlikely in the short term.

That all being said, Nio is a rapidly growing EV manufacturer with a huge footprint in Asia and ambitious expansion plans. The business could be one of the big winners of the green revolution. 

Of 34 analysts covering the stock listed by the Wall Street Journal, 27 rated the stock as a Buy. The analysts offered a consensus price target of $29.32 per share, compared with the current price of $14.77.